Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024
內克塔治療在Eular 2024大會上首次展示Nktr-0165的初步臨床數據,該藥是用於治療炎症性疾病的Tnfr2激動劑抗體。
Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024
內克塔治療在Eular 2024大會上首次展示Nktr-0165的初步臨床數據,該藥是用於治療炎症性疾病的Tnfr2激動劑抗體。
譯文內容由第三人軟體翻譯。